FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3164214892> ?p ?o ?g. }

• W3164214892 endingPage "433" @default.
• W3164214892 startingPage "433.1" @default.
• W3164214892 abstract "Background: Treatment of non-biologic-DMARD-IR 1 (DMARD-IR) and biologic-DMARD-IR 2 (bio-IR) PsA patients with upadacitinib (UPA) at 15 mg QD, an oral JAK1 selective inhibitor, resulted in significant improvement in signs and symptoms compared to placebo. Objectives: Using a pre-defined set of inflammation-related plasma protein biomarkers (pBM), to explore immunological pathway modulation by UPA 15 mg QD in PsA patients with active disease despite treatment with non-biologic or biologic DMARDs in the context of clinical response vs. non-response to treatment. Methods: Patients from the SELECT-PsA 1 (DMARD-IR) and the SELECT-PsA 2 (bio-IR) studies were randomly selected (PBO, n=100; UPA 15 mg QD, n=100 for each study). The levels of 92 inflammation related protein biomarkers (pBM) were analyzed using a multiplexed Proximity Extension Assay platform in plasma samples collected at baseline, week 2, and 12; change from baseline in protein levels was expressed as Log 2 Fold Change; a Repeated Measure Mixed Linear Model was used to identify pBM modulated by UPA compared to Baseline, and those differentially modulated between responders (R) and non-responders (NR) according to ACR50, PASDAS Minimal Disease Activity, and PASI75 at week 12. Correlation of disease activity measures with relative levels of pBM were derived using Pearson’s correlation; PASI score was transformed as Log 10 (x+1) prior to the analysis. Functional pathway prediction was performed in silico with a commercial distributed software. Results: At baseline, the relative levels of 37 pBM correlated with at least one baseline disease activity measure, with a marked positive correlation of IL6 with musculoskeletal end points (PASDAS and DAS28CRP), and a strong positive correlation of IL20, IL17A, IL17C, and TGFA with baseline PASI. At the single pBM-level, treatment with UPA 15 mg QD resulted in a down modulation of pBM associated with T cells, myeloid cells, and IFN-, IL6-, and TNF-related pathways in both DMARD-IR and bio-IR PsA patients. Overall effects of UPA on single pBMs were broadly similar between DMARD-IR and bio-IR patients. However, analysis of pBMs differentially modulated by UPA in R vs NR indicated that favorable clinical response (achievement of ACR50, PASDAS MDA, and PASI75) in DMARD-IR patients was associated with the down modulation of pBMs predicted to be linked to IFN, IL10, IL17, IL22, and IL27 pathways; while favorable clinical response in bio-IR patients was associated with the down modulation of multiple pBM predicted to be linked to the IL17, IL23, and IL1 pathways. Conclusion: UPA effects in both DMARD-IR and bio-IR PsA patients likely stem from the direct and indirect inhibition of multiple biological pathways belonging to the adaptive and innate immune systems. Responder/Non-Responder analysis suggests a possible shift from a TH1 biased biology in DMARD-IR PsA patients to a more TH17 biased biology in bio-IR PsA patients. This apparent change in the disease biology of PsA patients after inadequate response to prior therapy could be attributed to the actual alteration of the disease biology, treatment outcome-based patient selection, or both. Considering the clinical efficacy of UPA in both DMARD-IR and bio-IR PsA patients, this observation highlights the importance of targeting multiple pathways with drugs such as UPA for the treatment of a broad range of PsA patients. References: [1]McInnes, I. et al. Annals of the Rheumatic Diseases 79 , 16-17 (2020). [2]Mease, P.J. et al. Annals of the Rheumatic Diseases , annrheumdis-2020-218870 (2020). Acknowledgements: AbbVie funded this study and participated in the study design, research, analysis, data collection, interpretation of data, reviewing, and approval of the publication. All authors had access to relevant data and participated in the drafting, review, and approval of this publication. No honoraria or payments were made for authorship. Disclosure of Interests: Thierry Sornasse Shareholder of: AbbVie, Employee of: AbbVie, Jaclyn Anderson Shareholder of: AbbVie, Employee of: AbbVie, Koji Kato Shareholder of: AbbVie, Employee of: AbbVie, Apinya Lertratanakul Shareholder of: AbbVie, Employee of: AbbVie, Iain McInnes Consultant of: AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly, Gilead, Janssen, Novartis, Pfizer, Sanofi Regeneron, UCB Pharma, Grant/research support from: AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly, Gilead, Janssen, Novartis, Pfizer, Sanofi Regeneron, UCB Pharma, Christopher T. Ritchlin Consultant of: AbbVie, Amgen, Celgene, Janssen, Lilly, Novartis, Pfizer, Sun, UCB Pharma, Grant/research support from: AbbVie, Amgen, UCB" @default.
• W3164214892 created "2021-06-07" @default.
• W3164214892 creator A5028379115 @default.
• W3164214892 creator A5031269142 @default.
• W3164214892 creator A5039557070 @default.
• W3164214892 creator A5062649381 @default.
• W3164214892 creator A5064998879 @default.
• W3164214892 creator A5079480602 @default.
• W3164214892 date "2021-05-19" @default.
• W3164214892 modified "2023-10-17" @default.
• W3164214892 title "POS0407 PROTEOMICS ANALYSIS COMPARING THE MODE OF ACTION OF UPADACITINIB BETWEEN NON-BIOLOGIC-DMARD-IR AND BIOLOGIC-DMARD-IR PsA PATIENTS IDENTIFIES DISTINCT PATHOGENIC PATHWAYS IN THE SELECT-PsA 1 AND SELECT-PsA 2 PHASE 3 STUDIES" @default.
• W3164214892 doi "https://doi.org/10.1136/annrheumdis-2021-eular.1652" @default.
• W3164214892 hasPublicationYear "2021" @default.
• W3164214892 type Work @default.
• W3164214892 sameAs 3164214892 @default.
• W3164214892 citedByCount "0" @default.
• W3164214892 crossrefType "journal-article" @default.
• W3164214892 hasAuthorship W3164214892A5028379115 @default.
• W3164214892 hasAuthorship W3164214892A5031269142 @default.
• W3164214892 hasAuthorship W3164214892A5039557070 @default.
• W3164214892 hasAuthorship W3164214892A5062649381 @default.
• W3164214892 hasAuthorship W3164214892A5064998879 @default.
• W3164214892 hasAuthorship W3164214892A5079480602 @default.
• W3164214892 hasBestOaLocation W31642148921 @default.
• W3164214892 hasConcept C121608353 @default.
• W3164214892 hasConcept C126322002 @default.
• W3164214892 hasConcept C142724271 @default.
• W3164214892 hasConcept C143998085 @default.
• W3164214892 hasConcept C151730666 @default.
• W3164214892 hasConcept C203014093 @default.
• W3164214892 hasConcept C204787440 @default.
• W3164214892 hasConcept C27081682 @default.
• W3164214892 hasConcept C2779343474 @default.
• W3164214892 hasConcept C2780192828 @default.
• W3164214892 hasConcept C2781406297 @default.
• W3164214892 hasConcept C71924100 @default.
• W3164214892 hasConcept C86803240 @default.
• W3164214892 hasConcept C98274493 @default.
• W3164214892 hasConceptScore W3164214892C121608353 @default.
• W3164214892 hasConceptScore W3164214892C126322002 @default.
• W3164214892 hasConceptScore W3164214892C142724271 @default.
• W3164214892 hasConceptScore W3164214892C143998085 @default.
• W3164214892 hasConceptScore W3164214892C151730666 @default.
• W3164214892 hasConceptScore W3164214892C203014093 @default.
• W3164214892 hasConceptScore W3164214892C204787440 @default.
• W3164214892 hasConceptScore W3164214892C27081682 @default.
• W3164214892 hasConceptScore W3164214892C2779343474 @default.
• W3164214892 hasConceptScore W3164214892C2780192828 @default.
• W3164214892 hasConceptScore W3164214892C2781406297 @default.
• W3164214892 hasConceptScore W3164214892C71924100 @default.
• W3164214892 hasConceptScore W3164214892C86803240 @default.
• W3164214892 hasConceptScore W3164214892C98274493 @default.
• W3164214892 hasIssue "Suppl 1" @default.
• W3164214892 hasLocation W31642148921 @default.
• W3164214892 hasOpenAccess W3164214892 @default.
• W3164214892 hasPrimaryLocation W31642148921 @default.
• W3164214892 hasRelatedWork W1980998207 @default.
• W3164214892 hasRelatedWork W2081740839 @default.
• W3164214892 hasRelatedWork W2141447267 @default.
• W3164214892 hasRelatedWork W2276485219 @default.
• W3164214892 hasRelatedWork W2325745741 @default.
• W3164214892 hasRelatedWork W2414715318 @default.
• W3164214892 hasRelatedWork W2770702948 @default.
• W3164214892 hasRelatedWork W2790907679 @default.
• W3164214892 hasRelatedWork W4288740302 @default.
• W3164214892 hasRelatedWork W4362475233 @default.
• W3164214892 hasVolume "80" @default.
• W3164214892 isParatext "false" @default.
• W3164214892 isRetracted "false" @default.
• W3164214892 magId "3164214892" @default.
• W3164214892 workType "article" @default.